Current Report · Items 2.02, 9.01 · 8-K

IRIDEX Corporation

IRIXNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Filed Mar 26, 2026Accepted Mar 26, 2026, 4:22 PM EDTCIK 1006045Accession 0001193125-26-126323

Company context

Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

Current securities

IRIXNASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

IRIDEX CORPORATION · 8-K · Filed 2026-03-26

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.01 per share

Symbol: IRIX
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: C_d9b5c09e-8379-458a-9492-6b7a274b5f31

Dimensions: Not supplied

Accession 000119312526126323 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02. Results of Operations and Financial Condition. On March 26, 2026, IRIDEX Corporation (the "Company") issued a press release discussing its financial results for its fourth fiscal quarter ended January 3, 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Filed exhibits (1)

EX-99.1 (by filename) irix-ex99_1.htm

EX-99.1 2 irix-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Iridex Reports Fourth Quarter and Full Year 2025 Financial Results Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Financial Highlights • Generated total revenue of $14.7 million, representing growth of 16% year-over-year compared to $12.7 million in the prior year quarter • Cyclo G6® product family revenue was $3.8 million, representing growth of 15% year-over-year compared to $3.3 million in the prior year quarter o Sold 15,900 Cyclo G6 probes compared to 13,300 in the prior year quarter o Sold 44 Cyclo G6 Glaucoma Laser Systems compared to 47 in the prior year quarter • Retina product revenue was $8.9 million, representing growth of 22% year-over-year • Reduced operating expenses by 10…

Open exhibit ↗

Get the free weekly BCS email.